Sirtex Medical Limited posts big sales jump: Is it a $100 stock?

Fund Manager Hunter Hall claim Sirtex could be a $100 stock, but then they do own an awful lot of it!

| More on:

You鈥檙e reading a free article with opinions that may differ from The Motley Fool鈥檚 Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Sirtex Medical Limited (ASX: SRX) announced on Thursday that sales of its SIR-Spheres聽targeted radiation therapy for liver cancer grew 27.1% for the quarter ended 30 June 2014, compared to the previous corresponding period.聽The standout聽performer on a regional basis was the Americas with sales growth of 33%; Europe, Middle East and Africa grew 16.7%, and Asia Pacific 11.7%. Sirtex has now reported 40 consecutive quarters of dose sales growth and aims to聽accelerate that growth over the medium to聽long term.

Shares closed up 3.89% to聽$17.64聽and hit an all-time high in the process, with confirmation that the efficacy of Sirtex’s innovative liver cancer treatment is gaining wider acceptance amongst the global community of professional oncologists (cancer specialists) meaning the outlook appears brighter than ever. In November 2013 fund manager Hunter Hall, manager of the Hunter Hall聽Global Value Ltd (ASX: HHV) fund, declared Sirtex to have the potential to be a $100 stock. This on the basis that the聽company is able to penetrate 10% of聽its聽addressable market if the radiation-therapy聽treatment becomes recognised as the standard of care, rather than a treatment of last resort.聽In 2013 it’s estimated Sirtex penetrated just 1.4% of its addressable market.

The company聽posted revenues of $58.6 million聽for the聽first half of FY 2014聽and with sales up 19% and 27% on the previous corresponding periods for the second half, full-year revenues聽can be estimated at around $130 million. With Hunter Hall’s $100聽share price valuation based on future revenues of $830 million and EBITA of $565聽million, the prospect might not seem so fanciful after all. Investors should note Hunter Hall’s funds are significantly invested in Sirtex, so it’s no surprise that聽it’s happy to act as cheerleader in chief.

It’s also no surprise that Sirtex trades on a fruity 40 times projected earnings and investors should expect short-term price volatility. Especially because the company is expected to announce in late 2014聽the initial results of clinical trials intended to provide evidence that its cancer treatment should be promoted to use as a聽standard of care. If聽Sirtex is able to translate positive trial results into a quantum leap in revenues, the stock may run hard into the future. If the results from the studies disappoint the stock is likely to face selling pressure, although any investors left underwater would聽still own聽a growth business generating big聽profits.

Motley Fool contributor Tom Richardson owns shares in Sirtex Medical. You can provide feedback on Twitter tommyr345

More on 鈴革笍 Investing

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more

woman holds sign saying 'we need change' at climate change protest
ETFs

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
鈴革笍 Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
鈴革笍 Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more

asx share price competitions represented by businessmen arm wrestling
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more

asx investor daydreaming about US shares
鈴革笍 How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more

person reading news on mobile phone
鈴革笍 Investing

Why Fox (NASDAQ:FOX) might hurt News Corp (ASX:NWS) shareholders

News Corporation (ASX: NWS) might be facing some existential threats from its American cousins over the riots on 6 January

Read more